Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1B, Multicenter, Open-label Study to Determine the Safety, Pharmacokinetics and Preliminary Efficacy of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

NCT04434196 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT04434196
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04434196 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1B, Multicenter, Open-label Study to Determine the Safety, Pharmacokinetics and Preliminary Efficacy of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Lead sponsor
Celgene
Phase
Phase 1
Overall status
Completed
Start date
December 21, 2020
Completion date
May 21, 2024
Enrollment
16 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma, non-hodgkin